

**Algorithm, Clinical Highlights, Annotations**

Clinical Highlights: Added language addressing the goal of treatment of chronic pain to improve function “in the face of pain that may persist.”

- 3 Added language addressing referral or consult with specialist if there is diagnostic uncertainty.
  
- \* 4 & 5 The language addressing Fibromyalgia was moved from the muscle pain section to the neuropathic pain section as accumulating research suggests that fibromyalgia is a centrally mediated neuropathic pain syndrome, through consensus the work group identified that the neuropathic pain section better supported the evidence.
  
- 12 The CAGE-AID Screening tool was replaced with the CAGE questionnaire.
  
- 14 Additional language was added to the third Key Point to clarify role of the primary care physician in cognitive behavioral strategies.  
  
Current evidence was added supporting the use of the Chronic Care Model in the treatment of chronic pain.
  
- \* 15 Language addressing fibromyalgia as a special case within neuropathic pain was added to include effective pharmaceutical and non-pharmaceutical treatment recommendations.  
  
Drug therapies for neuropathic pain was updated.  
  
Language was revised addressing manipulative therapy.
  
- \* 19 Evidence added addressing NSAIDs and risk of bleeding.  
  
Section added addressing opioid management. Added additional examples of opioid and substance abuse assessment tools were added. These were also added in Key Implementation Recommendations.  
  
Language was added to opioid characteristics addressing nursing mothers, fentanyl, and methadone.  
  
The section “Other (non-tricyclic) antidepressants” was changed to “Other antidepressants – SSRI’s and SNRI’s.” Language was added addressing dual reuptake inhibitors.

Pharmaceutical treatments for fibromyalgia was updated.

Language was revised addressing transforaminal epidural injection and facet joint injection.

Appendix C: The Physical Ability Questionnaire (FAQ5) Information Sheet was added.

Appendix G: Content updated addressing methadone, FDA and Black Box warnings.

Appendix I: Content updated in Neuropathic Pain Treatment diagram.

Appendix J: Added a table of suggested maximum daily opioid doses for Primary Care Clinicians.

Guideline Summary: Updated and added Key Implementation Recommendations.

### **Priority Aims & Suggested Measures, Measurement Specifications**

Revised measure 2a, 2b, 2c, 3c, and 3d.

### **Support for Implementation**

Updated the Resources Available table.

*\*An asterisk indicates any changes in clinical practice recommendations*